Abstract:Objective To explore the preventing potential and mechanism of immature myeloid dendritic cell (iMDC) pulsed with immunodominant peptide α146-162 of Torpedo acetylcholine receptor (TAChR, Tα146-162-iMDC) in experimental autoimmune myasthenia gravis (EAMG). Methods (1) C57BL/6 mice were randomly enrolled into Tα146-162-iMDC group, iMDC group, control group and normal group respectively (n=6). On day 0, Tα146-162-iMDC group, iMDC group, control group were immunized with TAChR in CFA. On day 7, the mice of Tα146-162-iMDC group were subcutaneously injected with Tα146-162-iMDC. iMDC group and control group were subcutaneously injected with iMDC and PBS respectively. Normal group received no treatment. On day 14, lymphocyte proliferation of the four groups was measured. (2) C57BL/6 mice were randomly enrolled into prevention group and EAMG group ( n=12). On day 0, 30, 60, mice were immunized with TAChR in CFA to inducing EAMG. Mice in prevention group were subcutaneously injected with Tα146-162-iMDC 3 days later after each immunization while EAMG group received subcutaneous injection of PBS only. Clinical score of myasthenia were evaluated till the 90th days. (3) After the termination of experiment, lymphocyte proliferation were assayed. Levels of IFN-γ and IL-6 in the supernatants of leukomonocyte culture were measured by enzyme-linked immunosorbent assay. Results (1) The lymphocyte proliferative response after TAChR stimulation of Tα146-162-iMDC group, iMDC group, control group and normal group was (3314.1±571.3), (7717.5±1283.4), (8608.6±1458.9), (922.9±109.3)cpm respectively. Compared with iMDC group and control group, Tα146-162-iMDC group had a significantly suppressed antigen specific lymphocyte proliferation (P0.01). (2) The average clinical score of prevention group and EAMG group was 0.33±0.65 and 1.46±1.08 respectively. The accumulated incidence in prevention group and EAMG group was 25% and 75% respectively. There were significant differences of average clinical score (P0.01) and accumulated incidence (P0.05) between prevention group and EAMG group. (3) The lymphocyte proliferative response after TAChR stimulation of prevention group and EAMG group is (3347.6±556.9), (9416.2±1546.5) cpm. Compared with EAMG group, prevention group had a significantly reduced antigen specific lymphocyte proliferation (P0.01). (4) After lymphocyte stimulation with TAChR, the producing of IFN-γ of prevention group and EAMG group was (117.6±18.5) and (363.1±63.2) pg/ml respectively, and the producing of IL-6 of prevention group and EAMG group was (49.7±9.9) and (90.6±13.6) pg/ml respectively. Compared with EAMG group, the antigen specific secretion of IFN-γ and IL-6 in prevention group were significantly reduced (P0.01). Conclusions Tα146-162-iMDC can inhibit immunoreaction of T cells primed with TAChR and prevent EAMG. The immune tolerance induced by Tα146-162-iMDC is correlated with suppressed antigen specific lymphocyte proliferation and decreased secretion of IFN-γ and IL-6.

Experimental Studies on the Therapy of EAE with DT390-IL2 Recombinant Plasmid

Construction and Preliminary Investigation of a Plasmid Containing a Novel Immunotoxin DT390-IL-18 Gene for the Prevention of Murine Experimental Autoimmune Encephalomyelitis.

In vivo administration of plasmid DNA encoding recombinant immunotoxin DT390-IP-10 attenuates experimental autoimmune encephalomyelitis.

Antineuroinflammatory and neurotrophic effects of CNTF and C16 peptide in an acute experimental autoimmune encephalomyelitis rat model.

[An Expression Plasmid Encoding Recombinant Immunotoxin IP10-DT390 Suppresses the Experimental Autoimmune Encephalomyelitis].

C16 Peptide Shown to Prevent Leukocyte Infiltration and Alleviate Detrimental Inflammation in Acute Allergic Encephalomyelitis Model

Analysis of the Cellular Mechanism Underlying Inhibition of EAE after Treatment with Anti-Nkg2a F(ab′)2

Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES

Study on MCI-186 Treatment in Experimental Autoimmune Encephalomyelitis

Mechanism for Triptolide Amelioration of Experimental Autoimmune Encephalomyelitis

Effect of cannabinoid 1 receptor overexpression on mice with experimental autoimmune encephalomyelitis

[A Preparative Method of Chronic Experiment Autoimmune Encephalomyelitis].

Autoantigen-Pulsed Dendritic Cells Constitute A Beneficial Cytokine and Growth Factor Network in Ameliorating Experimental Allergic Encephalomyelitis

Combination of Apoptotic T Cell Induction and Self-Peptide Administration for Therapy of Experimental Autoimmune Encephalomyelitis

Effect of Cornel Iridoid Glycoside on Experimental Autoimmune Encephalomyelitis Attenuation Through JAK/STAT Signaling Pathway,at Least Partially

Therapeutic Potential Of Ifn-Gamma-Modified Dendritic Cells In Acute And Chronic Experimental Allergic Encephalomyelitis

Prevention of Experimental Autoimmune Myasthenia Gravis by Dendritic Cell Pulsed with Tα146-162

Establishment of Murine Experimental Autoimmune Encephalomyelitis Model and Study of the Immunologic Mechanisms

The Complexity of Cytokine Treatment in Ongoing EAE Induced with MBP Peptide 68–86 in Lewis Rats

Study on MR examination of experimental autoimmune encephalomyelitis mice.

Effects of Mycophenolate Mofetil on Neural Function of Experimental Autoimmune Encephalomyelitis in Rats